Hepatic Disease in HIV-Infected Patients
Summary
- Lamivudine is appropriate for use in HBV/HIV-coinfected patients if administered in combination with other agents with anti-HBV activity in the context of an antiretroviral therapy regimen (Management Guidelines)[DHHS ART]
- Incidence of lamivudine-resistant HBV is approximately 20% per year in HIV-infected persons and reaches 90% at 4 years[Dore 1999; Benhamou 1999; Pillay 2000]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content